Randomized Phase II study of the Addition of Targeted Therapeutic Agents to Tafasitamab-based Therapy in Non-Transplant-Eligible Patients With Relapsed/Refractory Large B-cell Lymphoma
- Sponsor:
- SWOG
- Sponsor Study ID:
- S2207
- CTO #:
- 104146
- NCT Number:
- NCT05890352
- Phase:
- II
- Protocol Type:
- Treatment
- Age Group:
- Adults
- Disease Sites:
- Non-Hodgkin's Lymphoma
- Study Objectives:
- To determine the recommended phase II dose of tafasitamab + lenalidomide + tazemetostat AND of tafasitamab + lenalidomide + zanubrutinib.
- eConsent:
- Not available
- Study Documents:
-
Open Study Documents
(MUSC NetID required for document access)
For more information about this trial please contact the study team:
-
Medical University of South Carolina
- Principal Investigator, Hess, Brian, at hessbr@musc.edu .
- Study Coordinator, Mendiola, Hannah, at mendiola@musc.edu .
Trial opened at the following institutions:
Medical University of South Carolina